AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 811,370 shares of the medical device company's stock after selling 211,284 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.66% of AtriCure worth $24,795,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of ATRC. Hood River Capital Management LLC grew its stake in shares of AtriCure by 3.3% during the fourth quarter. Hood River Capital Management LLC now owns 2,923,731 shares of the medical device company's stock worth $89,349,000 after purchasing an additional 93,131 shares in the last quarter. First Light Asset Management LLC boosted its stake in AtriCure by 5.6% in the fourth quarter. First Light Asset Management LLC now owns 1,969,221 shares of the medical device company's stock valued at $60,179,000 after acquiring an additional 103,685 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in AtriCure by 29.8% in the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after acquiring an additional 172,648 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in AtriCure by 24.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after acquiring an additional 136,015 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in AtriCure by 37.1% in the fourth quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after acquiring an additional 167,476 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, March 27th. Piper Sandler upped their price objective on shares of AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Canaccord Genuity Group decreased their price objective on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research note on Friday, March 28th. Stifel Nicolaus upped their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, UBS Group reduced their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, AtriCure presently has an average rating of "Moderate Buy" and an average target price of $50.67.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This represents a 25.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Vinayak Doraiswamy sold 2,500 shares of the stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $33.44, for a total transaction of $83,600.00. Following the completion of the sale, the insider now owns 73,550 shares in the company, valued at $2,459,512. This represents a 3.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.

AtriCure Stock Performance

NASDAQ ATRC traded up $0.46 during trading hours on Friday, hitting $34.54. 491,968 shares of the stock were exchanged, compared to its average volume of 648,882. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -36.36 and a beta of 1.57. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The stock has a 50-day moving average of $32.29 and a 200 day moving average of $34.68. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. The firm had revenue of $123.62 million during the quarter, compared to analysts' expectations of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The firm's revenue for the quarter was up 13.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.28) earnings per share. As a group, equities research analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.